Grifols Celebrates Initial Construction of New IVIG Facility with Los Angeles Officials...

Grifols Celebrates Initial Construction of New IVIG Facility with Los Angeles
Officials and Dignitaries

Grifols welcomes Los Angeles Mayor Antonio Villaraigosa, Cal State LA
President James Rosser, Councilman Hose Huizar, patient representatives and
other dignitaries for the construction dedication ceremony of its new IVIG
facility.

LOS ANGELES, Jan. 13 /PRNewswire/ -- Today, Grifols SA (Grifols), a global
healthcare company based in Barcelona, Spain, Grifols welcomes Los Angeles
Mayor Antonio Villaraigosa., Cal State LA President James Rosser, Councilman
Jose Huizar and other elected officials, patient representatives and
dignitaries for the ceremonial dedication of its new IVIG facility. Grifols,
a global healthcare company based in Barcelona, Spain, recently broke ground
on a new 92,000 square foot, intravenous immune globulin (IVIG) production
facility at its US headquarters in East Los Angeles. This new facility is the
initial realization of its $600 million long-range investment plan announced
in October 2007 to increase production for Grifols lifesaving therapies.

The new facility represents a $135 million investment in its facility in El
Sereno and will provide approximately 300 new high-paying jobs to Los Angeles.
"We are committed to growing Grifols operations in Los Angeles and to giving
back to the community through the creation of new quality jobs and economic
growth" said Gregory Rich, President of Grifols, Inc.

"Without the support of Mayor Villaraigosa and his business team, we would not
have been able to make our vision a reality in Los Angeles. This is the
first step in our long-range growth plans for Los Angeles and to meet
increasing patient needs for lifesaving plasma therapies."

"The bio-med industry is a critical component of the economic engine of Los
Angeles and I am pleased to support Grifols expansion and investment in our
great city. As the bio-med sector continues to grow, it will provide good,
high-wage jobs for Angelinos. I am glad that we were instrumental in
supporting Grifols expansion and allowing them to double their production
capacity for their lifesaving therapies" said Mayor Antonio R. Villaraigosa.

"We commend Grifols' increased commitment to the production of immune globulin
therapy. Assuring continued access to this lifesaving medicine means
countless people who live with primary immunodeficiencies, such as my son, can
lead healthy and productive lives," said Marcia Boyle, President and Founder
of the Immune Deficiency Foundation, the national patient organization for
persons with primary immune diseases.

Demand for IVIG has seen steady growth over the past ten years in the US,
Europe and other international markets. The dedication ceremony took place at
Grifols' US production campus and US corporate offices at 2410 Lillyvale, Los
Angeles on Tuesday, January 13, 2009 at 11:00 a.m. This unique event brought
together elected officials, representatives from national patient
organizations, and Grifols officials to celebrate the company's efforts to
ensure continued access to life-saving plasma medicines including IVIG.

About Grifols
Grifols SA (Grifols) is a global healthcare company founded in 1940 in
Barcelona, Spain. Today Grifols products and services are provided in more
than 90 countries around the world. Grifols specializes in the production of
plasma therapies to treat a variety of life-threatening diseases and
conditions. Grifols operates 80 plasma donor centers throughout the US and
has manufacturing facilities located in Barcelona, Spain and Los Angeles,
California. For more information about Grifols please visit www.grifols.com
or contact:

SOURCE Grifols SA

Chris Healey of Grifols, Inc., +1-703-351-5004, Fax; +1-703-276-9052,
Chris.Healey@Grifols.com